Release Date: April 23, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Usana Health Sciences Inc (USNA, Financial) reported a 12% year-over-year growth in consolidated net sales in constant currency, aligning with internal expectations.
- The company saw sequential growth in net sales and active customers in its largest market, mainland China, with increases of 6% and 4% respectively.
- Usana Health Sciences Inc (USNA) successfully expanded its product offerings in several markets, including a new chewable calcium product for children in China.
- The newly acquired Hiya business continues to deliver robust results with strong growth in net sales and active monthly subscribers.
- The company has proactively built inventory to mitigate potential tariff impacts and is exploring alternate sourcing relationships to address emerging trade policies.
Negative Points
- Consumer sentiment in key markets remains cautious, impacting overall business momentum.
- The potential impact of tariffs and trade policies remains highly uncertain, posing a risk to future financial performance.
- The India market is progressing slowly, with high expectations yet to be realized.
- Usana Health Sciences Inc (USNA) faces competition from products with artificial ingredients, requiring differentiation through natural product offerings.
- The integration of Hiya presents challenges in balancing synergy opportunities without overwhelming the existing team and strategy.
Q & A Highlights
Q: What are USANA's plans for additional incentives in China and South Korea, and how do they impact sales?
A: Brent Neidig, Chief Officer and Managing Director of China, explained that China had a strong quarter due to successful product promotions before the Chinese New Year. USANA plans to continue evaluating and implementing promotional incentives throughout the year to drive value for distributors and customers. South Korea also showed positive momentum, supported by a successful event in Nanjing with 13,000 attendees.
Q: Can you provide specifics on the timing and nature of new product launches planned for this year?
A: Doug Hekking, Chief Financial Officer, mentioned that product launches will occur systematically throughout the year, with a significant launch planned for early May. The focus is on product innovation, particularly in the children's health and wellness category, and exploring new channel opportunities to engage more customers.
Q: What are the synergy opportunities with the Hiya acquisition, and how are they being managed?
A: Walter Noot, Chief Operating Officer, stated that USANA is collaborating with Hiya on operational synergies, particularly in manufacturing and IT. Jim Brown, CEO, emphasized a systematic approach to avoid overwhelming Hiya and to ensure alignment with their strategic goals for 2025 and 2026. The benefits of these synergies will be realized gradually.
Q: How is USANA addressing potential tariff impacts, and what is the status of their inventory strategy?
A: Walter Noot explained that USANA has built up inventory, especially for nutritional products, to mitigate tariff exposure. Only 6% of raw materials come from China, reducing the impact. The company has also diversified sourcing to lessen potential tariff effects and has been proactive in manufacturing finished goods to prepare for tariffs.
Q: What new products have been launched in China, and what is the reception?
A: Brent Neidig highlighted the launch of a new chewable calcium product for children and other products through cross-border e-commerce channels, which were well received. Product introductions will accelerate in the second half of the year, with significant launches expected around the international convention in August.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
